Aurobindo Pharma receives USFDA approval for injectableAUROPHARMA - 1016 Change: -16.65 (-1.61 %)
News: Aurobindo Pharma’s subsidiary Eugia Pharma has received a USFDA final approval to manufacture and market Vasopressin Injection (USRLD: Vasostrict Injection of Par Sterile). The approved product has an estimated market size of ~ US$606 million (MAT June 2022, IQVIA).
View: Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock. The launch offers a window to ramp up revenues from US, depending on market share gains. US contributed 47% to FY22 sales to Aurobindo while company also aspires to achieve global sales of US$600-700 million by FY24 from global specialty business. We believe such launches are imperative for guided double-digit growth in injectable business.